PureTech Health PLC Transaction in Own Shares (4357Y)
03 Enero 2024 - 1:00AM
UK Regulatory
TIDMPRTC
RNS Number : 4357Y
PureTech Health PLC
03 January 2024
3 January 2024
PureTech Health plc
Transaction in Own Shares
PureTech Health PLC (the "Company") announces that it has
purchased the following number of its ordinary shares of one pence
each through Jefferies International Limited ("Jefferies"), as part
of its Share Buyback Programme, details of which were announced on
9 May 2022.
Date of purchase: 2 January 2024
Number of ordinary shares purchased: 12,161
Highest price paid per share: 188.00p
Lowest price paid per share: 186.20p
Volume weighted average price paid per
share: 187.73p
PureTech intends to retain the purchased shares in treasury.
Following the above transaction, the Company will have
17,626,589 ordinary shares in treasury and has 271,841,570 ordinary
shares in issue (excluding treasury shares). The total number of
voting rights in the Company is therefore 271,841,570 wh ich may be
used by shareholders in their calculations to determine if they are
required to notify their interest in, or a change to their interest
in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No
596/2014 (as incorporated into UK domestic law by the European
Union (Withdrawal) Act 2018) (the Market Abuse Regulation),
detailed information about the individual purchases is available
below.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to giving life to new classes of medicine to change the lives of
patients with devastating diseases. The Company has created a broad
and deep pipeline through its experienced research and development
team and its extensive network of scientists, clinicians and
industry leaders that is being advanced both internally and through
its Founded Entities. PureTech's R&D engine has resulted in the
development of 27 therapeutics and therapeutic candidates,
including two (Plenity(R) and EndeavorRx(R)) that have received
both U.S. FDA clearance and European marketing authorization and a
third (KarXT) that has been filed for FDA approval. A number of
these programs are being advanced by PureTech or its Founded
Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation
points.
For more information, visit www.puretechhealth.com or connect
with us on X, formerly known as Twitter, @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
Individual Transactions
Transaction Transaction Volume Price Platform Transaction Reference
Date Time (GBp) Number
02/01/2024 09:18:34 22 188 CHIX 00383801337TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 09:18:34 484 188 CHIX 00383801338TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 09:18:34 286 188 BATE 00383801340TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 09:18:34 174 188 BATE 00383801339TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 09:18:34 59 188 TRQX 00383801341TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 09:18:34 155 188 TRQX 00383801342TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 09:18:34 1012 188 XLON 00383801344TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 09:18:34 61 188 TRQX 00383801343TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 09:18:34 101 188 TRQX 00383801345TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 11:56:28 501 188 AQXE 00383822624TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 11:56:28 456 188 AQXE 00383822625TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 11:56:28 506 188 CHIX 00383822626TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 11:56:28 45 188 AQXE 00383822627TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 11:56:28 506 188 BATE 00383822629TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 11:56:28 46 188 BATE 00383822628TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 11:56:28 174 188 TRQX 00383822630TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 11:56:28 506 188 XLON 00383822631TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 11:56:28 506 188 XLON 00383822632TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 11:56:28 506 188 XLON 00383822633TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 12:08:00 1012 187.2 XLON 00383824162TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 12:46:17 94 188 CHIX 00383827576TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 12:46:17 412 188 CHIX 00383827577TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 12:46:17 208 188 XLON 00383827578TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 12:46:17 804 188 XLON 00383827579TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 12:46:21 216 187.6 BATE 00383827580TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:12:45 290 187.6 BATE 00383830138TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:12:45 275 187.6 TRQX 00383830139TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:12:45 506 187.4 XLON 00383830140TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:12:45 274 187.4 XLON 00383830142TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:12:45 506 187.4 XLON 00383830141TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:12:45 232 187.4 XLON 00383830143TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:12:46 318 186.6 CHIX 00383830144TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:12:46 188 186.6 CHIX 00383830145TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:12:46 44 186.6 CHIX 00383830146TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:12:46 56 186.6 CHIX 00383830147TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:21:49 214 186.2 XLON 00383831055TRLO0.1.1
------------ ------- ------- --------- ----------------------
02/01/2024 13:52:40 406 188 CHIX 00383834671TRLO0.1.1
------------ ------- ------- --------- ----------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
POSFLFEDLVIFIIS
(END) Dow Jones Newswires
January 03, 2024 02:00 ET (07:00 GMT)
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
